Purchase Order 75N91020P00364

<p>The National Cancer Institute awarded a purchase order to the University of California, Los Angeles for $21,139.00 on September 6, 2019. The order procures germline DNA samples and data from renal cell carcinoma patients for use in the National Cancer Institute's Renal Cell Carcinoma Genome-Wide Association Study. Work is performed in Los Angeles, California. The purchase order carries firm fixed-price pricing with an ultimate completion date of December 5, 2020.</p>

This is a $33,638.48 fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to the Centre International De Recherche SUR LE Cancer (IARC), a non-profit organization, for an &quot;International Collaboration for Cancer Classification and Research (IC3R).&quot; The contract has a completion date of September 20, 2024 and does not have a set-aside designation. IARC, the prime contractor, is the specialized cancer research agency of the World Health Organization,...

<p>The National Cancer Institute awarded a purchase order to Health Research, Inc. (Roswell Park Division) valued at $16,380.00 on June 4, 2019, for germline DNA samples and data from renal cell carcinoma patients to support the NCI's Renal Cell Carcinoma Genome-Wide Association Study. Work is performed in Buffalo, New York. The order carries a firm fixed price structure and a completion date of December 3, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $20,283.34 on April 24, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland. The order is set to complete by July 19, 2020.</p>

<p>The National Cancer Institute issued a $17,792.10 delivery order to Illumina, Inc. on January 13, 2020, for reagents and consumables.</p> <p>Place of performance is Bethesda, MD 20892. Ultimate completion date is February 12, 2020. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute issued a $26,365.32 delivery order to Roche Diagnostics Corporation on April 14, 2016, for in vitro diagnostic products and laboratory instruments.</p> <p>Place of performance is Bethesda, MD. The order was firm fixed price with no set-aside designation and an ultimate completion date of April 14, 2016.</p>

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc. valued at $19,814.32 on January 14, 2020, with final completion on February 21, 2020. The order is firm fixed price with no set-aside designation. Work is performed at the NIH Clinical Center in Bethesda, Maryland. The source does not specify the items or services procured under this order.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute issued a $5,217.50 delivery order to Illumina, Inc. on February 8, 2018, with an ultimate completion date of March 10, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>